Imunon, Inc., a clinical-stage biotechnology company, reported a net loss of $14.5 million for the fiscal year ending December 31, 2025, a decrease from a net loss of $18.6 million in the previous year. The company’s total operating expenses for 2025 were approximately $14.7 million, down from $19.1 million in 2024, primarily due to reduced research and development costs, which fell to $7.8 million from $11.6 million. As of December 31, 2025, Imunon had $8.8 million in cash and cash equivalents, reflecting a need for additional capital to support ongoing operations and development activities.
The company has made significant strides in its clinical programs, particularly with its lead candidate, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer. The program has progressed through multiple clinical trials, including the OVATION 2 and OVATION 3 studies. In 2025, the company initiated the OVATION 3 trial and reported encouraging results from the OVATION 2 trial, which indicated a median overall survival increase of 14.7 months for patients treated with IMNN-001 compared to standard care. Additionally, the company has completed dosing for its COVID-19 booster vaccine, IMNN-101, and is exploring its potential in the market.
Imunon’s operational metrics indicate a strategic focus on advancing its product pipeline. The company has not generated revenue from product sales and does not anticipate doing so in the near future. As of March 30, 2026, the company employed 20 full-time staff and has been actively pursuing partnerships and collaborations to enhance its research and development capabilities. The company’s stock trades on the Nasdaq under the ticker symbol "IMNN," and it has recently undergone a reverse stock split to maintain compliance with listing requirements.
Looking ahead, Imunon faces substantial challenges, including the need to secure additional funding to continue its operations and clinical trials. The company has expressed substantial doubt about its ability to continue as a going concern without raising further capital. Management plans to pursue various financing options, including equity sales and potential partnerships, to support its ongoing research and development efforts. The company’s future success will depend on its ability to navigate these financial challenges while advancing its clinical programs and achieving regulatory approvals for its drug candidates.
About Imunon, Inc.
Imunon is a biotechnology company developing DNA-based immunotherapies and vaccines. Its core platforms include TheraPlas for cancer treatment and PlaCCine for infectious disease vaccines, targeting solid tumors and pandemics like COVID-19. The company focuses on innovative, non-viral delivery systems to generate durable immune responses, with a pipeline emphasizing ovarian cancer immunotherapy and next-generation vaccines for emerging pathogens.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.